Menu Search
Equities

MedCap AB (publ)

MCAP:STO

MedCap AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)563.00
  • Today's Change20.00 / 3.68%
  • Shares traded9.15k
  • 1 Year change+83.09%
  • Beta0.7161
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year MedCap AB (publ) grew revenues 42.84% from 1.11bn to 1.59bn while net income improved 46.43% from 117.60m to 172.20m.
Gross margin46.63%
Net profit margin12.80%
Operating margin16.45%
Return on assets13.10%
Return on equity21.00%
Return on investment16.16%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at MedCap AB (publ) fell by 48.00m. However, the company earned 228.00m from its operations for a Cash Flow Margin of 14.36%. In addition the company used 152.30m on investing activities and also paid 119.70m in financing cash flows.
Cash flow per share22.80
Price/Cash flow per share23.63
Book value per share80.58
Tangible book value per share37.99
More ▼

Balance sheet in SEKView more

MedCap AB (publ) has a Debt to Total Capital ratio of 22.48%, a higher figure than the previous year's 21.45%.
Current ratio2.63
Quick ratio1.83
Total debt/total equity0.2912
Total debt/total capital0.2248
More ▼

Growth rates in SEK

Year on year, growth in earnings per share excluding extraordinary items increased 45.94%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)44.86
EPS (TTM) vs
TTM 1 year ago		50.97
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.